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ABSTRACT 
 
Lung cancer is recognized as one of the most devastating tumor worldwide 
due to the low rate survival over 5 years from the time of diagnosis. 
Inflammation has been widely recognized as the seventh hallmark of cancer as 
it facilitates the establishment/development and progression of lung cancer. In 
this context, recent evidence highlighted the role of the inflammasome during 
carcinogenesis. However, little is still known. The inflammasome is a 
multiprotein complex that leads to caspase-1 activation which role in lung 
cancer is still under investigated. In this context, the aim of my PhD project 
was to understand the role of the inflammasome in lung cancer in a mouse 
model of carcinogen-induced lung cancer and in human non-small cell lung 
cancer (NSCLC). We found that both caspase-1-dependent, the canonical 
pathway, and caspase-8/caspase-11-dependent, the non-canonical pathway, 
inflammasome were involved during lung cancer establishment and 
progression in both mice and humans. Our data showed that the 
pharmacological inhibition of both caspase-1 and caspase-8 significantly 
reduced lung tumor outgrowth associated to lower pro-inflammatory response 
and to a reduced lung recruitment of immunesuppressive cells and that 
caspase-8 was upstream caspase-1 activation during lung carcinogenesis. 
Furthermore, we showed that caspase-11 was the primary/main orchestrator of 
the inflammasome-dependent lung cancer progression and that the enzyme 
could be upstream of caspase-1 to induce the amplification of the occurring 
inflammatory process associated to lung cancer development. Finally, we 
identified a  novel mechanism by which lung tumor-associated macrophages 
could favor lung tumorigenesis via the activation of caspase-11-dependent 
inflammasome and the consequent release of the pro-tumorigenic IL-1α.  
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Lung cancer is a devastating disease that counts more deaths than other solid 
tumors, with a 5-year survival rate of 10%
1
. The number of new cases is 
expected to rise by about 70% over the next two decades. More dramatically, 
over half of people with lung cancer die within one year of being clinically 
diagnosed due to a still unmet medical need: 1. lack of prevention and early 
detection tools and 2.  recognition of the symptoms at the sole late stages
1
. To 
note, the sole computed tomography (CT) scan and surgical resection 
accompanied by chemo- and radiotherapy are actually the options for lung 
cancer patients. 
The actual chemotherapy for lung cancer patients includes inhibitors of cell 
proliferation (i.e. carboplatin, docetaxel, gemcitabine). Besides their side 
effects, the efficacy of these drugs is very low and more importantly they are 
preferred after surgical resection. Other innovative drugs are represented by 
anti-angiogenesis therapy (antibodies against vascular endothelial growth 
factor, VEGF) and by epidermal growth factor receptor (EGFR) blockade 
(erlotinib), anaplastic lymphoma kinase (ALK) inhibitors (crizotinib, ceritinib, 
and alectinib) and the recent discovered anti-PD-1 antibodies (nivolumab and 
pembrolizumab). While anti-PD-1 antibodies proved efficacy in melanoma 
patients, they are still an imperfect therapeutic tool for lung cancer patients, 
who still have a low survival rate even after the association with anti-CTLA4 
antibody (ipilimumab)
2
. Therefore, two major issues raise: 1. the classical 
chemotherapy is not as efficient as the proliferation rate of neoplastic cells, 
which overcomes the pharmacological efficacy in favour of high risk side 
effects; 2. the percentage of patients that can be treated with the above 
innovative drugs (i.e. nivolumab) are around 20-30% with a relative survival 






. Therefore, it is obvious that there is a clinical unmet need for lung 
cancer patients. 
In order to attempt a novel therapeutic approach for lung cancer patients, we 
started from a hallmark of lung cancer, chronic inflammation. Several lines of 
studies evidence that chronic inflammation underlies lung carcinogenesis. The 
proposed role of chronic inflammation in the tumorigenic process is based on 
a 2-stage model of carcinogenesis
4
, during which tumor formation involves an 
initiating event, such as a genotoxic injury, followed by promotional events 
and/or conditions that result in clonal growth of transformed cells. In this 
context, chronic inflammatory responses have been proposed as an 
endogenous (sterile) source of mutational events: the altered frequency of cell 
proliferation and of metaplasia in epithelial tissues can contribute to 
regenerative events that while they intend to replace the damaged epithelium, 
they turn into enhancing the probability of somatic mutations, especially in an 
inflammatory microenvironment. In addition, in response to a variety of 
inflammatory cytokines genotoxic metabolites by neighbouring epithelial and 
stromal cells can also be produced. Moreover, many tumors are associated 
with the infiltration of inflammatory cells that in most cases, due to their 
immune-suppressive nature, are related to a bad prognosis
5,6
. Chronic 




Therefore, the prolonged contact of respiratory epithelial cells and the lining 
immune cells with insulting molecules can initiate and sustain inflammatory 
responses. Epidemiological studies revealed that lung chronic inflammation 
initiate/promote the development of lung malignancy, possibly in conjunction 
with tobacco use and/or other environmental pollutants (i.e. asbestos, silica, 
diesel exhaust)
4
. Indeed, elevated serum levels of C-reactive protein (CRP) are 
associated, together a particular lifestyle (i.e. smoking, air pollutant exposure) 
to increased risk of lung cancer
10,11




inflammatory cytokines, such as IL-1β and IL-18, are detected in the plasma 
and tissue of lung cancer patients, identified as bad prognostic biomarkers
12
. 
IL-1-like cytokines (i.e. IL-1α, IL-1β, IL-18 and IL-33) are identified as 
‘alarmins’. Their expression is tightly regulated by multiprotein complexes 
referred to as ‘inflammasomes’
13
.  
The inflammasome is a multicomplex system that comprises the activity of 
several proteins that promote caspase-1 activation (Figure 1)
13
. Endosomal and 
extracellular Toll-like receptors (TLRs) and the cytoplasmic NOD-like 
receptors (NLRs) are a class of sentinel receptors that are pivotal in the 
detection of pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs) (Figure 1)
13,14
. The cooperation 
between these two systems allows to ‘sense’, and respond to a large number of 
infectious and sterile insults. Initially, NLRs were proposed to regulate 
inflammation through apoptosis, but nowadays this concept has been modified 
in that NLRs may serve as sentinels for cellular distress
14,15
. Several NLRs 
species have so far been identified in both humans and mice, i.e., NLRP1, 
NLRP3, NLRP6, NLRC4, AIM2
15
. These proteins recognize distinct signals 
and, most importantly, are expressed at different levels. Full activity of 
NLRP3, the most studied NLR to date, requires two signals: the first induces 
its expression, along with synthesis of pro-IL-1β, via NF-κB activation, and 
the second activates NLRP3 that assembles to the adapter protein apoptosis 
associated speck-like protein containing a CARD domain (ASC) for the 
activation of caspase-1 (Figure 1)
13,15
. In contrast, NLRC4 and AIM2 are 
constitutively expressed in hematopoietic cells and are triggered by flagellin-
like molecules and dsDNA, respectively
15
. The common activity to all NLRs 
is the activation of caspase-1 which converts pro-IL-1β and pro-IL-18 into 









Figure 1. The inflammasome is a multicomplex system which activation is 
induced either directly by specific PAMPs and/or DAMPs or by the two-signal 
model as in the case of NLRP3. The recognition of PAMPs and/or DAMPs by 
extracellular or cytoplasmic TLRs leads to the activation of NF-κB (first 
signal), which in turn promotes the transcription of pro-IL-1β/IL-18 or some 
NLRs (e.g. NLRP3). NLRs assemble into the inflammasome complex which 
via the CARD domain can recruit pro-caspase-1 and promote its autocatalytic 
cleavage (second signal). Caspase-1 can lead to a cascade of pro-inflammatory 
events via the activation of pro-IL-1β and pro-IL-18, which then interact with 
their own membrane receptors amplifying the inflammatory response. On the 
other hand, active caspase-1 can lead to cell pyroptosis with the consequence 
of membrane rupture and release of such alarmins as IL-1α and high mobility 









The third effector mechanism of the inflammasome activation, besides the 
release of the active IL-1β and IL-18, is the induction of pyroptosis, a cell 
death process that requires the activity of  caspase-1 and a critical mechanism 
by which inflammasomes contribute to host responses against Gram-negative 
and Gram-positive bacteria
15
. Pyroptotic cell death has been well described in 
the hematopoietic cell lineage but it can also occur in stromal cells such as in 




Alternative, non-canonical inflammasomes have also been described, which 
engage caspase-11 (also known as caspase-4/5 in humans). This in turn 
induces inflammasome-dependent caspase-1 activation and inflammasome-
independent, pyroptosis-like cell death, via the release of such ‘alarmins’ as 
IL-1α and high mobility group box 1 (HMGB1)
17
.  
Because IL-1α/β, IL-18 and pyroptosis have the potential to damage the host, 
tight control of these pathways is critical for the prevention of chronic 
inflammation. These processes are key steps for the regulation of programmed 
cell death, differentiation and proliferation
16
, three aspects that in the context 
of cancer represent the rheostat for tumor proliferation versus tumor 
arrest/regression (Figure 2). 
In the face of an ever-expanding bulk of literature on the role of 
inflammasome in host defense, little is known about its role in lung cancer. So 
far, in the context of tumor microenvironment, the activation of the 











Figure 2. Chronic inflammation is at the interface between cells injury 
resolution and tumorigenesis. The activation of the inflammasome in epithelial 
cells, dendritic cells and macrophages maybe responsible for chronic 
inflammation at the basis of lung carcinogenesis. Therefore, the 
inflammasome complex may represent the rheostat for tumor 







Pro-tumor activity of the inflammasome. Epidemiological studies showed 
that high serum concentrations of pro-inflammatory inflammasome-related 
cytokines, e.g. IL-1β/IL-18, are correlated to malignancies with low-rate 
survival from time of diagnosis
18
. These cytokines, together with TNF-α and 
IL-6, which can be induced by IL-1-like cytokines
19
, are involved in cell 
proliferation and survival
20
, as well as cell adhesion and migration
21,22
, all 
features of tumor progression and invasiveness.  
In the tumor microenvironment, IL-1-like cytokines can be secreted by both 




. Tumorigenesis, tumor 
progression and dissemination, and tumor immune-editing are affected by the 
presence or not of these cytokines which can mediate a variety of local and 
systemic activities. 
 
Figure 3. The exposure to carcinogens or intrinsic genetic aberrations are at 
the basis of cancer initiation. The activation of the inflammasome in epithelial 
cells, dendritic cells and macrophages may lead to different immune responses 
according to the tumor microenvironment
13




IL-1α is an alarmin that under physiological conditions is present into the cell 
in its precursor form
24





, with the ensuing inflammation/necrosis 
and subsequent adaptive immune responses
27
. In a model of 







, IL-1α is released by dying cells, stimulating oxidative 
stress pathways responsible of local inflammation and in some cases of cell 
rescue from death to provide tissue regeneration and subsequent accumulation 
of mutations and tumor initiation/progression
31
. In support of these findings, 
IL-1α-induced IL-6 activates STAT-3 and promotes liver as well as gastric 
tumorigenesis
28–30
. An indirect evidence for IL-1α-dependent tumor outgrowth 







 tumor lesions. Besides its role in tumor-
associated inflammation, IL-1α activity was also associated to the activity of 
mutated K-Ras, one of the main oncogenes, which in turn induced constitutive 
activation of NF-κB and AP-1 that on one side promoted an autocrine loop for 
further IL-1α expression/secretion, and on the other increased tumor burden in 
a mouse model of pancreatic carcinoma
35
. In sharp contrast, in a mouse model 
of methylcholanthrene (MCA)-induced fibrosarcoma IL-1α knockout mice had 
similar tumor lesions as wild type mice
31
. This implied that it was not 
implicated in tumor outgrowth, but rather, cell-membrane exposed IL-1α 
exerted anti-tumor activity in that it edited tumor immune-surveillance via the 




 T cells. Some cancer cells can express 
membrane IL-1α, which can increase the immunogenicity of tumor cells and 
promote anti-tumor immune surveillance and tumor regression. However, high 




Similarly, IL-1β and IL-18 have contrasting roles in the tumor milieu. IL-1β 




cells, and mediates leukocyte migration
36
. IL-18 can cooperate with IL-12 
toward Th1 polarization and activation of NK cells, and can also promote 
Th17 responses in the presence of IL-23
37
. In the absence of IL-12 and IL-23, 
IL-18 can vice versa lead to a Th2-bias
37
. Therefore, depending on the 
microenvironment, IL-1β and IL-18 can facilitate tumor-associated 
inflammation, rendering the tumor stroma carcinogenic via the release of 
trophic factors such as fibroblast growth factor 2 (FGF2) and VEGF which 
allow malignant cells, cancer-associated fibroblasts (CAFs) and endothelial 
cells to fuel and foster tumor cell survival and invasiveness
38
. In addition, IL-
1β induces IL-6, whose pro-tumorigenic activity is mediated through the 
activation of STAT-3 in an IL-6 receptor (IL-6R)-dependent manner
39
. 
Similarly, IL-1β can induce TNF-α synthesis/release which in some 
circumstances can act as an anti-tumor factor
40
, but in others can participate to 
the recruitment of suppressive immune cells, such as myeloid-derived 
suppressor cells (MDSCs), which favor the neoplastic growth and 
progression
41
. In support of the pro-tumorigenic potential of IL-1β, the 
inoculation of lung cancer cells engineered to express higher levels of this 
cytokine results in higher aggressiveness and dissemination
42
. Moreover, in 
transgenic mice parietal cells of the stomach able to constitutively secret high 
level of IL-1β, spontaneously developed gastric inflammation and 
tumorigenesis correlated to the recruitment of MDSCs, through an IL-1R/NF-
κB-dependent pathway
43
. IL-1β secreted by ovarian cancer cells suppresses 




Another mechanism by which the inflammasome may contribute to immune 
responses is the secretion of other pro-inflammatory cytokines, such as 
HMGB1, considered as an endogenous DAMP, and to the induction of growth 
factors such as FGF2
45
, via as yet unclarified biochemical mechanisms. 
Caspase-1 is essential for FGF2 secretion by macrophages
46




IL-18, IL-1α, HMGB1 and FGF2 are not processed by caspase-1
46–48
, 
suggesting an indirect activity of the inflammasome in the regulation of these 
unconventional proteins. The activation of fibroblast growth factor receptor 1 
(FGFR1) in mammary epithelial cells resulted in increased expression of 
inflammatory mediators, particularly IL-1β, which cooperate to promote 
hyperplastic lesions in the mammary gland
49
. In addition, inflammasome-
dependent IL-1β exerted pro-carcinogenic activity by suppressing NK and T 
cell-mediated antitumor actions and immune-editing in a mouse model of 
carcinogen-induced sarcoma and metastatic melanoma
50
. It is important to 
note, though, that these proteins might directly depend on caspase-1-mediated 
pyroptosis. In this context, an intriguing role was identified for caspase-11, 
which is engaged in the non-canonical inflammasome molecular pathways
51
. 
While caspase-11 is not critical for caspase-1 activation upon LPS stimulation, 
it can mediate the activation of the NLRP3 inflammasome during 
endotoxemia
17,52
 and lead to caspase-1 maturation and IL-1β release from 
infected macrophages. In support of this notion, caspase-11-deficient mice 
produce lower levels of IL-1β and IL-18
52
. In addition, LPS stimulation fails 
to secrete normal levels of IL-1β in NLRP3, ASC and caspase-1 deficient 
macrophages, implying a cross-talk between caspase-1 and caspase-11 
activity
53
. Therefore, the engagement of caspase-11 can induce 
inflammasome-dependent caspase-1 activation and inflammasome-
independent pyroptosis-like cell death, via the release of such ‘alarmins’ as IL-
1α and HMGB1
17
. However, little is known about caspase-11 inducer/s. 
TLR4/TRIF-dependent type I IFN production has been reported to promote 
caspase-11 activation downstream of NLRP3 activation
54,55
. On the other 
hand, though, type I IFNs can induce iNOS expression, leading in turn to 







Anti-tumor activity of the inflammasome. In sharp contrast, several studies 
have highlighted an anti-carcinogenic role for inflammasome; particularly, it 
had a protective role in preventing tumor formation in a Dextran Sodium 
Sulphate-Azoxymethane (DSS-AOM) mouse model of colon carcinoma
58,59
, 
and its absence increased pro-inflammatory cytokines levels, ERK, NF-κB and 
STAT3 activation. Similarly, IL-18 was shown to mediate anti-cancer effects 




Despite conflicting opinions, there is growing evidence that inflammasome 
and its products have an essential role in stimulating adaptive immune 
responses, such as those involved in anticancer immunosurveillance
13
. Indeed, 
it was also demonstrated that the inflammasome and subsequent IL-1β priming 
of T cells is critical for immune-mediated eradication of tumors following 
chemotherapy
61
. Nevertheless, IL-1β was demonstrated to facilitate an 
immunesuppressive/tolerant response that in the tumor microenvironment 
reflects into cancer progression.  
Therefore, it is obvious to speculate that the inflammasomes have pleiotropic 
and sometimes contrasting roles in multiple facets of oncogenesis: they 
positively affect cell-autonomous death pathways and anticancer 
immunosurveillance, but they also stimulate autocrine or paracrine processes 
that favor carcinogenic inflammation, tumor growth, metastasis and 
angiogenesis. To date, the inflammasome involvement represents a double 
edged sword in that it still remains to be understood if its activation during the 
neoplastic transformation/cells proliferation or pharmacological treatment can 





Aim of the research project. Based on these notions, according to which the 
inflammasome may influence the formation, progression and therapeutic 
response of cancer through its contribution to tissue homeostasis, 
inflammation and immune responses
13
, the aim of my PhD project was to 
investigate inflammasome-dependent pathway/s involved in lung cancer 
establishment and progression. In particular we tried to understand the 
involvement of the canonical and non-canonical inflammasome-dependent 
pathways in lung cancer establishment and progression. We pursued our goal 
by following specific aims:  
1
st
 year: investigate the role of canonical inflammasome in the malignant 
transformation/progression of lung cancer focusing on immunosuppressive 
response/s, responsible of oncogenesis; 
2
nd
 year: evaluate the role of non-canonical, caspase-8-dependent 
inflammasome in lung carcinogenesis;  
3
rd
 year: evaluate the role of non-canonical, caspase-11-dependent 







Caspase-1-dependent canonical inflammasome was involved in lung 
cancer establishment and progression. 
 
1.1 Introduction 
Caspase-1, formerly called as IL-1β converting enzyme (ICE), is a member of 
a family of nine cysteine proteases that seem to be uniquely involved in the 
inflammatory response by cleaving the precursors of IL-1β, IL-18, and IL-33. 
Indeed, the rate-limiting step in IL-1β or IL-18-dependent inflammation is the 
activation of caspase-1
14
. Inactive pro-caspase-1 is converted to an active 
enzyme following homodimerization that allows  an autocatalytic cleavage 
that releases the active enzyme composed of two large and two small subunits. 
The autocatalysis of pro-caspase-1 to active caspase-1 is tightly controlled by 
the inflammasome assembly
62
. Caspase-1 activation can also induce 
pyroptosis, an inflammatory cell death that is accompanied by the release of 
IL-1β and IL-18 which elicits local inflammation
63
. Although various studies 
demonstrated that an increased concentration of IL-1β protein in tumor tissues 
was associated to poor prognosis for cancer patients
64
, the function of 
inflammasomes in tumor growth and metastasis remains controversial. 
Published studies mainly use AOM/DSS-induced colon cancer as an animal 
model to evaluate the involvement of inflammasomes in cancer
59,60
. Results 
from those studies indicate that inflammasome components (i.e. NLRs) 
provide protections against tumorigenesis in colitis-associated colon cancer, as 
mice deficient for inflammasomes, including NLRP3, NLRP12, NLRC4 and 
caspase-1, have increased tumorigenesis in the AOM/DSS-induced colon 
cancer animal model due to lower cell death rate
58
. However, in other types of 
cancer, such as melanoma and mesothelioma, caspase-1-dependent canonical 
inflammasomes and IL-1β have been shown to enhance tumor growth
64
. 




progression accompanied by decreased myeloid cells recruitment in preclinical 
breast cancer models
64
. According to the lack of data in lung cancer and to the 
conflicting results reported in literature, we focused on the role of caspase-1-
dependent canonical inflammasomes during lung cancer establishment and 
progression using human non-small cell lung cancer (NSCLC) tissues and a 
mouse model of carcinogen-induced lung cancer.  
We find that caspase-1 is in its active form in both human and mouse lung 
cancer tissues compared to non cancerous tissues. In support, the 
pharmacological inhibition of caspase-1 by means of a specific inhibitor (Ac-
Y-Vad) significantly decreases lung tumor development in mice. This effect is 
associated to a reduced release of pro-inflammatory cytokines and recruitment 
of immunosuppressive cells to the lung of tumor-bearing mice. These data 
demonstrate that caspase-1 activation occurs during lung carcinogenesis in 







1.2 Materials and Methods 
Human Samples. Human tissue of NSCLC and non-cancerous lung tissues 
were obtained from patients undergoing thoracic surgery at the Hospital of 
Salerno “San Giovanni di Dio e Ruggi D’Aragona”. The protocol was 
approved by Ethics Committee and patients signed the informed consent. The 
mean age of patients was 60±10 years and equally distributed for gender. We 
excluded subjects with metastatic lung carcinoma.  
Cancerous tissues (LC) were obtained from the tumor mass whereas ‘non–
lung cancerous tissues’ (NLC), derived from a distant portion of the tumor 
mass. Human samples were collected within 12 hours from the surgery and 
processed within the following 3 hours.  
Mice. Female C57Bl/6 mice (6-8 weeks; Charles River, Lecco, Italy) were 
maintained in specific pathogen-free conditions at the University of Salerno, 
Department of Pharmacy. All animal experiments were performed under 
protocols that followed the Italian (DL No. 26/2014) and European 
Community Council for Animal Care (Directive 2010/63/EU) on the 
protection of animals used for scientific purposes.  
Experimental Protocol. To investigate the role of caspase-1-dependent 
canonical inflammasome in the establishment/progression of lung carcinoma, 
a carcinogen-induced mouse model of lung cancer was used. Under isoflurane 
anaesthesia, N-methyl-N-nitrosourea (NMU), an alkylating and mutagen 
agent
65
, was intratracheally (i.t.) instilled into C57Bl/6 mice (female; 6-8 
weeks of age) for three consecutive weeks, according to the following 
protocol: 50μg/mouse (in 10 μl of saline) at t=0 followed by other two 
administrations of 10μg/mouse (in 10 μl of saline) at t=7 days and t=14 days 
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Figure 4. Experimental protocol: C57Bl/6 mice (female, 6-8 weeks of age) 
were intratracheally (i.t.) exposed to N-methyl-N-nitrosourea (NMU) for three 
consecutive weeks at the dose of 50µg/mouse at week 1 (t=0), and at the dose 
of 10µg/mouse at week 2 (t=7) and 3 (t=14). Mice were sacrificed at different 





In an initial set of experiments, immunofluorescence analyses were performed 
on left lung criosections obtained from NMU-exposed mice in order to define 
first the establishment of the lung tumor mass and then to indentify tumor 
hystotype generated. Left lung criosections were analysed for the presence of 
Ki-67 (Dako, Cambridge, UK), K-Ras, p63 and cytokeratin 5 (K5) (Santa 
Cruz technologies, CA, USA). Alexa-Fluor-555 and FITC staining were used 
to identify the above biological targets. Images were observed by means of 
Carl Zeiss confocal microscopy (magnification: 40X) (Figure 5). According to 
a blind pathologist, the lungs of NMU-exposed mice sacrificed at 7 days 
showed inflamed lesions, whereas hyperplastic/tumor lesions were visible 
starting at 4 weeks in the lung of NMU-treated mice
66
. In our experimental 




post the first NMU exposure. Tumor incidence was analysed as the percentage 
of tumor formation of each lung compared to the average of all tumor 
area/total lung area of n=39 mice exposed to NMU. Moreover, NMU-exposed 
mice showed that the tumor was adenocarcinoma-like according to 





















 tumor cells in the 




Mice were divided into the following groups: 1. Naïve, non-treated, mice; 2. 
Control (CTR), i.t. instilled with NMU; 3. NMU-instilled mice treated with 
Ac-Y-Vad (y-VAD; 1-10μg/mouse), a specific caspase-1 inhibitor.  
Animals were sacrificed at different time points (3, 7 and 28 days) to study the 
involvement of caspase-1 during lung cancer development and progression. 
Bronchoalveolar lavage (BAL) fluid was obtained by using a solution of PBS 
(0.5 mL) and EDTA (0.5 mM) to measure cytokine levels. Lungs were excised 
for staining and biochemical tests. Left lung lobes were embedded into OCT 
medium to perform Haematoxylin & Eosin (H&E) staining to evaluate the 
tumor lesion, expressed as ratio of Tumor Lesion Area/Total Lung Area, 
calculated with ImageJ software (NIH, USA); whereas, right lung lobes were 
divided into two parts: one part underwent digestion with 1U/mL of 
collagenase to perform flow cytometry analyses, and the other underwent  
homogenization to perform ELISAs  and western blotting analyses. 
Flow Cytometry Analysis. Cell suspensions, from digested lungs, were 
passed through 70 μm cell strainers and red blood cells were lysed. To 
investigate the immune infiltrates into the lung of tumor-bearing mice, lung 
cell suspensions were labelled with specific antibodies: CD11b, Gr-1, CD4, 
CD25, FoxP3. 
Cytokine measurements. IL-6, IL-1α, IL-1β, IL-18, IL-33, TNF-α and IL-10 
were measured in lung homogenates (expressed as pg/mg of proteins) and in 
BAL (expressed as pg/mL) by using commercially available ELISAs 
(eBioscience, CA, USA; R&D Systems, London, UK).  
Western blot analysis. Lung homogenates were used to examine the 
expression of caspase-1 active form (20-10 kDa) vs the precursor form (46 
kDa) (Santa Cruz Technologies, CA, USA).  
Statistical analysis. Results are expressed as median±interquartile range and 
analysed with Mann Whitney test for non parametric data. P values less than 




1.3 Results  
1.3.1 Caspase-1 was active in both humans and mice during lung 
carcinogenesis. 
The active form of caspase-1 is involved in the release of the mature IL-1β and 
IL-18, highly present in the serum and lung of cancer patients
18
. Because of 
the conflicting data in literature about the pro- or anti-tumorigenic role of 
caspase-1, and thus of the inflammasome, in carcinogenesis and due to the 
lack of an experimental carcinogen-induced mouse model for lung cancer, our 
main goal was to first establish a mouse model of carcinogen-induced lung 
cancer and then understand inflammasome involvement in lung 
carcinogenesis, by comparing the experimental model to human samples of 
NSCLC. As already described in materials and methods section of this 
Chapter (paragraph 1.2), NMU-exposed mice showed an adenocarcinoma-like 
lung lesion, which established at 28 days (4 weeks) after the first NMU 
exposure (Figure 5), preceded by lung inflammation due to the exposure of the 
carcinogen, as also demonstrated by the release of pro-inflammatory cytokines 
at 7 days (i.e. IL-6 and TNF-a, Figure 10A and 10B below). In order to 
understand the involvement of caspase-1 in a time-dependent manner in lung 
carcinogenesis, western blotting analyses were performed on lung 
homogenates obtained from NMU-exposed mice sacrificed at 3-7-28 days 
(Figure 6). Caspase-1 was present in the lung of NMU-exposed at 3, 7 and 28 
days compared to naïve mice (Figure 6A and 6B). To note, the expression of 
the active form was significantly higher at 7 days compared to 3 and 28 days 
post NMU exposure (Figure 6B), implying the activation of the enzyme post 
the genotoxic injury, which led to an inflammatory response that to the 
establishment of lung tumor mass starting at 28 days. In order to verify 
whether the activation of caspase-1 and thus of the canonical pathway of the 
inflammasome occurred in human lung cancer, we used lung tissues of non-




undergoing thoracic surgery. Similarly to mice, caspase-1 was in its active 
form (20 kDa) in human LC tissues (n=7) but not in NLC tissues (n=7) (Figure 
7A and 7B).  
 
Taken together, these results demonstrate that caspase-1 is in its active form in 
both human lung cancer samples and in a mouse model of lung carcinoma, 
implying that rather than inducing cell death or defense mechanisms, as 
described in literature
63
, it is involved in tumor proliferation.  
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B
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Figure 6. Caspase-1 was active in the lung of tumor-bearing mice exposed 
to NMU. A) Western blot analyses, performed on lung homogenates obtained 
from NMU-exposed mice, showed higher levels of the active form of caspase-
1 (20 kDa) at 3, 7 and 28 days compared to naïve mice. B) Quantitative 
analysis (ratio active vs precursor form of caspase-1) showed higher levels of 
the active form of caspase-1 in lung tumor-bearing mice.  
Data are expressed as median±interquartile range and analysed with Mann 
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Figure 7. Caspase-1 was active in human samples of non-small cell lung 
cancer (NSCLC) patients. A) Representative western blotting analyses 
performed on human samples of NSCLC showed caspase-1 in its active form 
in LC but not in NLC tissues. B) Data were stated as ratio of the active (20 
kDa) vs precursor (46 kDa) form of caspase-1, expressed as 







1.3.2 Pharmacological inhibition of caspase-1 reduced lung cancer 
progression in mice modulating the pro-inflammatory pathways.  
In order to evaluate whether the activation of caspase-1 was pivotal for lung 
cancer establishment/progression, we used a specific pharmacological 
inhibitor, Ac-Y-Vad (y-VAD). y-VAD was administrated, intraperitoneally 
(i.p.), at 1 or 10μg/mouse/twice/week from time 0 after NMU instillation up to 
the time of sacrifice of mice (Figure 8A). We observed that the administration 
of the low dose of y-VAD (1μg/mouse) did not alter tumor lesion at 28 days (4 
weeks) (Figure 8B). In sharp contrast, the higher dose of y-VAD 
(10μg/mouse) significantly reduced lung tumor lesion compared to control 
mice (Figure 8B), suggesting an important role of caspase-1 during lung tumor 
establishment/progression. With these results, a question was obvious: what 
happens if caspase-1 is inhibited when the tumor is already formed? 
Therefore, another set of experiment was set up: mice were treated with y-
VAD (1-10µg/mouse) twice a week starting from day 28 after the first NMU 
instillation, when the tumor lesion was already formed. Mice were sacrificed 7 
days after y-VAD administration (35 days). In this type of experiments, the 
sole administration of y-VAD 10μg/mouse, but not of y-VAD 1μg/mouse, 
significantly reduced lung tumor lesions compared to control mice (Figure 
8C). To further prove, the relevance of caspase-1, we used caspase-1 ko mice, 
which were later identified as caspase-1/11 double knock-out (DKO) mice. 
The genetic absence of caspase-1 significantly reduced tumor lesions in the 
lung of NMU-exposed mice at 28 days post the first NMU exposure (Figure 
9). However, it is to note that the tumor lesion in DKO was 0.048±0.0074 
(Figure 9) versus 0.077±0.076 (Figure 8B) in mice treated with y-VAD 
(10µg/mouse), implying the involvement of another orchestrator in lung tumor 
environment, as described in Chapter 3.  
In our preliminary data we  observed that caspase-1 was in its active form at 




lung was characterized by an inflamed status (materials and methods section, 
paragraph 1.2) after the exposure to the alkylating/genotoxic agent NMU. 
Therefore, to better understand the role of caspase-1 in tumor-related 
inflammation, we went on by analyzing the release of pro-inflammatory 
cytokines in the tumor microenvironment by using homogenized lung tissues 
and BAL from NMU-exposed mice. The administration of y-VAD 
10μg/mouse significantly reduced the release of the pro-inflammatory IL-6 
(Figure 10A) and TNF-α (Figure 10B). In sharp contrast, the direct 
inflammasome-dependent cytokines IL-1β and IL-18 did not show any 
reduction after y-VAD treatment. In particular, IL-1β levels were significantly 
increased at 28 days (Figure 10C), and IL-18 levels (Figure 10D) were 
unchanged compared to control as revealed in the BAL obtained from tumor-
bearing mice compared to the control group. In addition, the levels of IL-1α 
(Figure 10E) and IL-33 (Figure 10F) were significantly reduced in y-VAD-
treated than in control lung homogenates obtained from tumor-bearing mice. 
To note, IL-1α and IL-33 are not strictly dependent on caspase-1 activation
54
.  
Taken together, our data show that caspase-1 is involved in the amplification 
of the inflammatory process associated to lung cancer establishment and 
progression in mice. However, the canonical inflammasome-dependent 
pathway is not altered in terms of IL-1β and IL-18 release, after the inhibition 
of caspase-1 in mice, instead associated to lower lung tumor burden (Figure 
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Figure 8. Pharmacological inhibition of caspase-1 reduced lung cancer 
progression in mice. A) Experimental protocol. B) The administration of y-
VAD 10μg/mouse/twice/week from time 0 after NMU instillation, 
significantly reduced lung tumor formation at 28 days compared to control 
mice. C) In another set of experiments, mice were treated with PBS (CTR) or 
y-VAD 1-10μg/mouse at 28 days after the first exposure to NMU. y-VAD 
10μg/mouse, but not y-VAD 1μg/mouse, significantly reduced lung tumor 
lesion compared to control mice. Tumor lesion was expressed as ratio between 
tumor area and total lung area. Data are expressed as median±interquartile 




















Figure 9. The genetic absence of caspase-1 reduced lung cancer 
establishment/progression in mice. Caspase-1/11 knock-out (ko), identified 
as double ko (DKO), were exposed to NMU as for CTR mice. DKO mice 
showed lower tumor lesion than CTR mice. Data are expressed as 






































































































































































Figure 10. The pharmacological inhibition of caspase-1 reduced pro-
inflammatory cytokine release, but not inflammasome-dependent 
cytokines. Broncho-aleveolar lavage (BAL) fluid was harvested from NMU-
exposed mice at 7 and 28 days. The pharmacological inhibition of capase-1 by 
means of y-VAD 10μg/mouse  significantly reduced the levels of IL-6 (A) and 
TNF-α (B), but not of IL-1β (C) and IL-18 (D) in the BAL of lung tumor-
bearing mice. Similarly, the levels of IL-1α (E) and IL-33 (F) were 
significantly reduced in lung homogenates obtained from control and y-VAD-
treated NMU-exposed mice. Data are expressed as median±interquartile range 




1.3.3 Inhibition of caspase-1 modulated the immune-suppressive 
microenvironment in the lung of tumor-bearing mice. 
Growing evidence indicates that the immune system is pivotal for malignant 
disease control
68
. The suppressive immunity has been acknowledged for its 
contribution to cancer development and progression
68,69
, due to the immune
 
system failure to attack malignant cells as ‘non-self’. Based on this concept, 
we moved on by analyzing the immune lung tumor microenvironment after 
caspase-1 inhibition. The inhibition of caspase-1 by means of y-VAD 
(10g/mouse) reduced the recruitment to the lung of immunosuppressive cells 












cells) compared to the control group (Figure 11A and 11B respectively). These 
results were consistent with the decrease of tumor lesion observed in y-VAD-
treated mice. However, the levels of IL-10, immunosuppressive cytokine, in 
the BAL of both control and y-VAD-treated mice did not show any 
statistically significant difference, though higher in CTR mice than y-VAD-
treated mice (Figure 11C).  
Taken altogether, these data suggest that the pharmacological inhibition of 
caspase-1 interferes with the recruitment of immune-suppressive cells to the 
















































































Figure 11. The pharmacological inhibition of caspase-1 modulated the 
immunesuppressive microenvironment in the lung of tumor-bearing mice. 
The pharmacological inhibition of caspase-1 significantly reduced the 












 cells) (B). IL-10 levels in the BAL of control (CTR) and 
y-VAD-treated lung tumor-bearing mice did not show statistically significant 
differences, but they were higher than naïve mice (C). Data are expressed as 
median±interquartile range, analysed with Mann Whitney test for non-





The activation of the inflammasome in the context of tumor microenvironment 
has yielded to conflicting results, and details of its involvement in lung cancer 
are very ill-defined. Here we show that caspase-1 is involved in lung 
inflammation and then lung tumor formation/progression in mice. Similarly, 
human samples of lung cancer tissues show that caspase-1 is in its active form, 
implying the activation of the inflammasome. In support, the pharmacological 
inhibition of caspase-1 significantly reduces both the establishment and the 
progression of the lung tumor area in mice.  
The incidence of lung tumor is associated to chronic infections, inhaled 
pollutants, cigarette smoking
21,70,71
. According to the sterile inflammation 
theory, sterile, noninfectious insults, such as reactive oxygen species (ROS), 
oxidized and/or methylated DNA, HMGB1, heat shock proteins, ATP, 
generally identified as DAMPs, can induce chronic inflammation
26,72
. All 
these stimuli can behave as tumor promoters, which underlying activity is the 
induction of chronic inflammation that, rather than providing a protective 
response to loss of tissue homeostasis, can aberrantly facilitate tumor 
development. These insults, both endogenous and exogenous, are sensed by 
the multimeric complex called inflammasome
14
. In our human samples, that 
derived majorly from smokers, we observed that caspase-1 was in its active 
form
73
. To date, these patients showed higher content of mitochondrial ROS in 
peripheral blood-derived mononuclear cells (PBMCs) (data not shown), 
following particulate matter exposure
73
. In our published data
73
, we showed 
that the ultrafine particles (UFP) induced the activation of the inflammasome 
in a NLRP3-caspase-1-dependent manner. These latter data, correlated to the 
data in this thesis about the activation of caspase-1 in the lung tumor lesion of 
lung cancer patients, suggest that the activation of the inflammasome plays a 
role in lung cancer, despite what reported in literature about its anti-




had increased the susceptibility and number of colon polyps in a DSS-AOM 
mouse model of colon carcinoma, showing that the inflammasome has a 
protective role in preventing tumor formation in the colon
74
. This effect was 
ascribed to the induction of cell death after caspase-1 activation. In sharp 
contrast, in our experimental and human lung cancer samples we did not 
observe the induction of cell death via apoptosis. We analysed both the levels 
of the active form of caspase-3 and caspase-9 that are involved in cell death. 
We did not observe any activation of these two caspases and even more, we 
observed no reduction of the anti-apoptotic protein Bcl-2 (data not shown), 
implying that the activation of caspase-1 is not involved in cell death in lung 
cancer establishment and progression in both mice and humans.  
To prove caspase-1 as of potential therapeutic target, we performed 
experiments during which caspase-1 was pharmacologically inhibited by a 
commercially available specific inhibitor, y-VAD. We show that the 
pharmacological inhibition of caspase-1 by means of y-VAD significantly 
reduces lung cancer outgrowth associated to lower pro-inflammatory response 
and to a reduced lung recruitment of immunosuppressive cells. However two 
main issues raised from these experiments: 1. the genetic absence of caspase-1 
further reduced the tumor area in NMU-exposed mice which was 
0.048±0.0074 versus the tumor area observed in y-VAD treated mice, which 
was 0.077±0.076; 2. the pro-inflammatory pattern (i.e. TNF-α and IL-6, IL-1α 
and IL-33), non strictly dependent on inflammasome activation was reduced in 
y-VAD-treated NMU-exposed mice, but instead IL-1β and IL-18, strictly 
dependent from the inflammasome activation were not altered.  
These two issues have a common explanation. Caspase-1 ko mice were 
discovered as double ko mice in that they lack both caspase-1 and caspase-
11
17
, implying that another orchestrator upstream caspase-1 was involved. In 
the meanwhile, a paper from Dr Kannenganti’s group was published, showing 




responsible of the activation of IL-1β and IL-18 in bone marrow-derived 
macrophages
75
. Therefore, two questions were opened: is caspase-8 active in 
our samples and is it upstream responsible for caspase-1 activation? Or is 
caspase-11 upstream caspase-1 activation? These two questions were 
approached and tried to be answered in Chapter 2 and 3. 
Moreover, the immunesuppressive environment is altered in y-VAD-treated vs 
CTR mice in that MDSCs and Treg are lower recruited to the lung of NMU-
exposed mice, although we do not detect differences in IL-10 levels, most 
probably due to partial reduction of inflammasome pathway involved in lung 
carcinogenesis. In support, we already proved that human lung tumor lesions 
are populated by immunesuppressive cells
76,77
 in which the activation of the 
inflammasome plays a pivotal role for the immunesuppression/tumor 
progression axis.  Of note, oxidized DNA, highly relevant during tumor 
initiation/progression, potentiates stimulator of IFN I genes (STING)-
dependent signaling pathways
78
, which is responsible for immune-
regulatory/suppressive responses via the activity of indoleamine-2,3-
dioxygenase (IDO) in DC
78
 and for the recruitment and differentiation of Treg 
in tumor masses
79
. Similarly, we proved that plasmacytoid DCs (pDCs) 
released IL-1α and IL-1β in a caspase-1-dependent manner in human lung 
tumor lesions, favoring cancer progression
76
.  
In conclusion, these first data demonstrate that the activation of the 
inflammasome via caspase-1 is involved in lung tumor establishment and 
progression, favoring the immunesuppressive environment that allows tumor 
cells to escape the immune system activity. To date, though, we believe that 
another orchestrator, upstream caspase-1, governs the inflammasome 
activation in favor of lung carcinogenesis. This hypothesis has been 






Caspase-8-dependent non-canonical pathway of inflammasome was 
involved during lung cancer establishment and progression. 
 
2.1 Introduction 
Caspase-8 is an apical caspase which initiates programmed cell death 
following death receptor ligation
80
. This central role in apoptosis has prompted 
significant clinical interest in promoting caspase-8 expression and activity as 
therapeutic opportunity in cancer. Nonetheless, caspase-8 expression is 
heterogeneous and sometimes even elevated in tumors; therefore, some doubt 
still remain as to whether its expression correlates with clinical benefits. To 
note, one of the main mechanism for chemotherapy resistance is associated to 
the evasion of tumor cells to the apoptotic, non-inflammatory, cell death
81
. 
Caspase-3 and -9 represent the main caspase effectors that lead to the 
apoptotic cell death
82
. However, other caspases underlying apoptosis-mediated 
cell death occur. In this scenario, caspase-8 is one of the upstream mediator of 
cell death which activation is related to TNF-like cytokines, such as TNFα, 
Fas ligand (FasL; CD95)
82
. Caspase-8 is a cysteinyl protease which is 
activated through the formation of a death-inducing signaling complex when 
death receptors are complexed to their specific ligands. Engagement of death 
receptors such as CD95, TNF-related apoptosis-inducing ligand (TRAIL) and 
TNF receptor 1 (TNFR1) results in recruitment of caspase-8 and its adaptor 
Fas-Associated protein with Death Domain (FADD) to initiate an apoptosis 
cascade that leads to caspase-3 (extrinsic) dependent and caspase-9 (intrinsic) 
dependent pathways
82
. However, although the fine relation between apoptosis 
and inflammation has been separated for years, caspase-8 has been recently 
demonstrated to mediate the canonical and noncanonical NOD-like receptor 
family, pyrin domain containing 3 (NLRP3) inflammasome priming and 
activation
75




IL-1β release from macrophages in a canonical, but also in a non canonical, 
manner by promoting the activation of caspase-1. Indeed, caspase-1/11 
knockout macrophages were still able to release IL-1β under infection 
conditions
83
. In this context, though, caspase-8 inhibits the kinase RIP3, which 
is involved in necrosis and predominates on caspase-8-induced apoptosis
84,85
. 
Notably, mice deficient of caspase-8 were embrionic lethal, explaining the 
important role of caspase-8 to alter the necrotic cell death, but also to induce 
proliferation, as demonstrated in T lymphocytes
86
. Activated T lymphocytes 
were induced to proliferation under caspase-8 control that led to NF-kB and 
MAPK activation. In this scenario, caspase-8 can therefore be categorized as 
both apoptotic/non-inflammatory caspase and pro-inflammatory caspase 
together with caspase-1 and caspase-11.  
Caspase-8 was inactivated in a variety of human cancers
87
, which may 
promote tumor progression as well as resistance to current treatment 
approaches. Shivapurkar and colleagues, described that caspase-8 was silenced 
in small cell lung cancer (SCLC), suggesting that its absence was responsible 
for tumor cell chemoresistance under TRAIL stimulation
88
. In contrast, Riley 
and colleagues
81
, demonstrated that pro-caspase-8 was overexpressed in 
NSCLC and represented a marker for poor patient prognosis. To date, caspase-
8 has also been found to play a number of non-apoptotic roles in cells, such as 
promoting activation NF-κB signaling, regulating autophagy, altering 
endosomal trafficking and enhancing inflammatory pathways, cellular 
adhesion and migration. Therefore, based on these concepts, caspase-8, 
depending upon the specific cellular context, may either potentiate or suppress 
tumor malignancy. 
Therefore, the aim of our study was to understand and clarify the role of 
caspase-8 in human lung cancer, taking advantage of a mouse model of 





2.2 Materials and methods 
To investigate the role of caspase-8-dependent non-canonical inflammasome 
in the establishment/progression of lung carcinoma, human samples obtained 
from lung cancer patients and a mouse model of carcinogen-induced lung 
cancer were used, as discussed in the materials and methods section in Chapter 
1, paragraph 1.2.  
Experimental Protocol. Briefly, C57Bl/6 mice (female; 6-8 weeks of age) 
(Charles River, Lecco, Italy) were exposed to N-Methyl N-Nitroso Urea 
(NMU), intratracheally (i.t.), under anaesthesia with isoflurane. Similarly to 
Chapter 1, we followed the experimental protocol as described in Figure 4 
paragraph 1.2. Moreover, in this set of experiments, NMU-exposed mice were 
intraperitoneally (i.p.) treated with z-IETD-FMK (IE: 0.5μg/mouse), specific 
inhibitor of caspase-8, twice a week starting from the first exposure to NMU 
(Figure 14A). In particular, mice were divided into the following groups: 1. 
Naïve, non-treated, mice; 2. Control (CTR), NMU-instilled; 3. IE, NMU-
instilled mice treated with z-IETD-FMK (IE; 0.5μg/mouse) and 4. y-VAD 
10+IE, NMU-instilled mice treated with Ac-y-Vad (10μg/mouse)+z-IETD-
FMK (0.5μg/mouse).  
The animals were sacrificed at different time points (7 and 28 days) to study 
the involvement of caspase-8 during lung cancer development and 
progression. Left lung lobes were embedded into OCT medium to perform 
H&E staining to evaluate the tumor lesion, expressed as Tumor Lesion 
Area/Total Lung Area. Right lung lobes were homogenized with 1U/mL of 
collagenase (Sigma Aldrich, Rome, Italy) to evaluate the release of cytokines 
and immune cells infiltrates to the lung. 
Broncho-alveolar fluid (BAL) was collected by means of airway lavage by 
using a solution of PBS (0.5mL) and EDTA (0.5mM) to measure pro-




Flow Cytometry Analysis. Lungs were isolated and digested as described 
above. To investigate the immune infiltrates into the lung of tumor-bearing 
mice, lung cell suspensions were labelled with specific antibodies (CD11c, 
CD11b, B220, F4/80, Gr-1, PDCA-1, MHC I, MHC II, CD3, CD4, CD25, 
FoxP3). 
Cytokine measurements. IL-6, IL-1α, IL-1β, IL-18, IL-33, TNF-α and IL-10 
were measured in lung homogenates (expressed as pg/mg of proteins) and in 
BAL (expressed as pg/ml of proteins) by using commercially available 
ELISAs (eBioscience, CA, USA; R&D Systems, London, UK).  
Western blot analysis. Lung homogenates were used to examine the 
expression of caspase-8 active form (22 kDa; Santa Cruz Technologies, CA, 
USA). Similarly, c-FLIP and Bcl-2 (Santa Cruz Technologies, CA, USA) 
expression was evaluated.  
Statistical analysis. Results are expressed as median±interquartile range and 
analysed with Mann Whitney test for non-parametric data. P values less than 





2.3.1 Caspase-8 was active in both human and mouse samples of lung 
cancer. 
Evasion of apoptosis is considered to be one of the hallmarks of human 
cancers
8
. Cell death is executed by caspases and several upstream regulatory 
factors, which direct their proteolytic activity. Often these regulatory factors, 
in addition to being potent apoptosis inducers, function in cell survival or 
repair signaling pathways in response to cellular stress. Since caspase-8 
presents a key regulator of apoptosis, inactivation of caspase-8 can confer 
resistance to cell death. Genetic, epigenetic as well as posttranslational 
changes can contribute to inactivation of caspase-8 in human malignancies
87
. 
Thus, restoration of caspase-8 function represents a promising strategy to 
either directly trigger apoptosis in cancer cells or to restore sensitivity to 
apoptotic stimuli. In order to investigate the role of caspase-8 in lung cancer 
establishment and progression, human samples of NSCLC were enzymatically 
digested and tested to evaluate its expression. Western blotting analyses 
showed that both Non Lung Cancer (NLC) and Lung Cancer (LC) tissues had 
similar levels of the active form (22 kDa) of caspase-8 compared to the 
precursor form (55 kDa) (Figure 12A and 12B).  
Because of the dichotomy of caspase-8 in human samples, we took advantage 
of the established carcinogen-induced lung cancer mouse model (Figure 14A). 
Mice were sacrificed at different time points, after 7 and 28 days from the first 
NMU exposure. Western blotting analyses showed that the active form of 
caspase-8 (22 kDa) was solely present in the lung of tumor-bearing mice at 
both 7 and 28 days post NMU administration, compared to naïve, non-treated 
mice (Figure 13A and 13B). Taken together, these results appear in contrast in 
that Caspase-8 is in its active form in both human lung cancer tissues and in 




absent of macroscopically and clinically detectable tumor lesions, still had 
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Figure 12. Caspase-8 was active in human samples of NSCLC patients. A) 
Representative western blotting analyses performed on human samples of 
NSCLC. Non lung cancer (NLC) and lung cancer (LC) samples had similar 
levels of the active form of caspase-8 (22 kDa) (B). Data were expressed as 
ratio of the active (22kDa) vs precursor (55 kDa) form of caspase-8, analyzed 
by means of Image J Software (NIH, USA). Data are expressed as 
medians±interquartile range and analyzed by using Mann Whitney test for 
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Figure 13. Caspase-8 was active in the lung of NMU-exposed mice. A) 
Western blot analyses performed on lung homogenates obtained from tumor-
bearing mice. B) Quantitative analysis (ratio active vs precursor form of 
caspase-8) showed higher levels of the active form of caspase-8 in lung tumor-
bearing mice. Data are expressed as medians±interquartile range and analyzed 





2.3.2 Pharmacological inhibition of caspase-8 reduced lung cancer 
progression in mice. 
To evaluate the role of caspase-8 during lung cancer 
establishment/progression, we used a pharmacological inhibitor of the 
enzyme, z-IETD-FMK (IE 0.5μg/mouse) (Figure 14A). Surprisingly, the 
administration of IE robustly reduced lung tumor growth compared to control 
mice (CTR) (Figure 14B and 14C), demonstrating that caspase-8 was involved 
in lung tumor progression. In addition, we also performed another set of 
experiments during which caspase-8 was inhibited only after lung tumor 
formation at 28 days post the first NMU exposure and mice were sacrificed at 
35 days. Again, the administration of IE significantly reduced lung cancer 
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Figure 14. Pharmacological inhibition of caspase-8 reduced lung cancer 
progression in mice. A) Experimental protocol. B) The administration of z-
IETD-FMK (IE) significantly reduced lung tumor formation in a time 
dependent-manner, as shown by H&E pictures in panel C. D) The inhibition 
of caspase-8 at 28 days after the first exposure to NMU significantly reduced 
lung tumor lesions in mice. Experiments were performed in three different 
experimental days. Data are expressed as medians±interquartile range and 




2.3.3 Caspase-8 was involved in pro-inflammatory, but not in cell death, 
pathways during lung carcinogenesis.  
Caspase-8 is an apical caspase which initiates programmed cell death 
following death receptor ligation
82
. To understand the role of caspase-8 in 
apoptosis-induced cell death in our mouse model, we went on by analysing the 
expression of Bcl-2, well-known anti-apoptotic protein
89
. Bcl-2 was highly 
expressed in the lung of tumor-bearing mice (Figure 15A and 15B) as well as 
in naïve mice (Figure 15B). However, the pharmacological inhibition of 
caspase-8 by means of IE did not alter the expression of the anti-apoptotic Bcl-
2 in the lung of NMU-exposed mice compared to control mice sacrificed at 
both 7 and 28 days (Figure 15A and 15B). In contrast, the expression of the 
short segment of c-FLIP (c-FLIPS 28 kDa), involved in the apoptotic cell 
death, was detectable at 28 days in IE-treated tumor-bearing mice compared to 
the control group (Figure 16A and 16B). Long segment of c-FLIP (c-FLIPL 51 
kDa) was expressed in both control and IE-treated mice (Figure 16A and 16B). 
Similarly, human tissue of lung cancer (LC) only had the long segment of c-
FLIP compared to the short segment, which instead was higher in non 
cancerous (NLC) lung-derived tissues (Figure 16C), explaining the dichotomy 
of caspase-8 activation in non-cancerous samples (Figure 12A and 12B).  
To note, caspase-8 has also been found to play a number of non-apoptotic 
roles in cells, such as promoting the activation of the pro-inflammatory NF-
κB-dependent signalling
86
. NF-κB controls the transcription of many pro-
inflammatory cytokines involved in inflammation-driven carcinogenesis and 
tumor progression
13
. The administration of IE significantly reduced the release 
of IL-6 (Figure 17A), TNF-α (Figure 17B), IL-18 (Figure 17C), but not of IL-
1β at 28 days (Figure 17D) from the BAL obtained from the lung of NMU-
exposed mice compared to the CTR group. In addition, the levels of IL-1α 




NMU-exposed mice than in CTR lung homogenates obtained from tumor-
bearing NMU-exposed mice.  
Taken together, our data show that caspase-8 is involved in the amplification 
of the inflammatory process associated with lung cancer in mice. Instead, its 
pro-apoptotic activity is strictly related to the presence of the short segment of 












































Figure 15. Involvement of Caspase-8 in the apoptotic cascade. Lung tumor-
bearing mice presented high levels of Bcl-2 (25 kDa) (A and B), which were 
not reduced after IE treatment at both 7 and 28 days. Results are expressed as 
median±interquartile range (n=7). Experiments were performed in two 























NLC  LC NLC  LC NLC  LC NLC  LC NLC  LC
































Figure 16. Caspase-8 pro-apoptotic activity was associated with the 
expression of the short segment of c-FLIP. The levels of the short segment 
of c-FLIPs (28 kDa) was significantly increased in the lung of NMU-exposed 
mice treated with IE (A and B). Western blot analyses were performed on lung 
homogenates and expressed as ratio between the target protein vs GAPDH or 
Hsc70 (loading control). C) Western blotting analyses showed that human 
cancerous samples (LC) of NSCLC patients were characterized by the 
presence of the sole long isoform of c-FLIP (51 kDa) compared to the ‘non 
lung cancer’ (NLC) counterpart which instead presented higher levels of the 
short segment of c-FLIP (28 kDa). Experiments were performed in two 
different experimental days. Data are expressed as medians±interquartile range 























































































































































































Figure 17. The pharmacological inhibition of caspase-8 reduced pro-
inflammatory cytokine release.  Broncho-aleveolar lavage (BAL) fluid was 
harvested from lung tumor-bearing mice at both 7 and 28 days post NMU 
exposure. The pharmacological inhibition of capase-8 by means of IE 
significantly reduced the levels of IL-6 (A), TNF-α (B), IL-18 (C)  but not of 
L-1β at 28 days (D) in the BAL of lung tumor-bearing mice. Similarly, the 
levels of IL-1α (E) and IL-33 (F) were significantly reduced in lung 
homogenates obtained from control and IE-treated tumor-bearing mice. Data 
are expressed as medians±interquartile range and analyzed by using Mann 




2.3.4 Inhibition of caspase-8 modulated the innate immune 
microenvironment in the lung of tumor-bearing mice. 
Tumor immunoediting has been widely described as pivotal for the success of 
immunotherapy
90
. Therefore, we moved on by analysing the immune 
microenvironment in the lung of tumor-bearing mice treated with IE. The 







) in IE-treated tumor-bearing mice compared to control 





) were significantly reduced into the lung of tumor-
bearing mice treated with IE compared to control (Figure 18B). In contrast, IE 







) compared to the control group (Figure 18C), although  
these cells were not in their active form, as we were not able to detect any 
difference in MHC I/II onto the lung of myeloid DC from control and IE-














) (Figure 18E) did not show any statistical differences 
between control and IE-treated mice. This latter effect was confirmed by the 
unaltered levels of IL-10 in the BAL of both control and IE-treated mice 
compared to naïve mice (Figure 18F). 
Taken altogether, these data imply that although the pharmacological 
inhibition of caspase-8 diminishes the pro-inflammatory humoral pattern of 
lung tumor microenvironment, it does not interfere with the recruitment of 
immune-suppressive Treg to the lung of tumor-bearing mice, differently from 
what observed for caspase-1 (Figure 11B, Chapter 1), implying that its 














































































































































































Figure 18. The pharmacological inhibition of caspase-8 modulated the 
immune microenvironment in the lung of tumor-bearing mice. The 
pharmacological inhibition of caspase-8 significantly reduced the percentage 






 cells) (A), and myeloid-




 cells) (B), but not of 




 cells) (C), plasmacytoid 






 cells) (D) and T 






 cells) (E). F) IL-10 levels in 
the BAL of control (CTR) and IE-treated lung tumor-bearing mice were not 
altered, but higher than naïve mice. Experiments were performed at least in 
two different experimental days. Data are expressed as medians±interquartile 




2.3.5 Caspase-8 was upstream caspase-1 activation during lung 
carcinogenesis in NMU-exposed mice. 
Data obtained showed that the active form of caspase-8 was involved in lung 
cancer in both humans and in a mouse model of lung carcinoma. The 
pharmacological inhibition of the enzyme by means of IE significantly 
reduced lung cancer outgrowth (Figure 14B and 14C) associated to lower pro-
inflammatory response (Figure 17), confirming our main hypothesis about the 
involvement of the inflammasome in lung cancer. However, as discussed in 
Chapter 1, even the pharmacological inhibition of caspase-1 significantly 
reduced lung cancer establishment/progression (Figure 8B), although it did not 
reduce IL-1β and IL-18 in the BAL of tumor-bearing mice, implying that 
caspase-1 may act in a non-inflammasome dependent manner or that another 
orchestrator might govern the effect of caspase-1 in our mouse model of lung 
cancer.  
Concurrently to our study, Gurung P. et colleagues demonstrated that caspase-
8 was an upstream regulator of the canonical inflammasome in bone marrow-
derived macrophages (BMDMs) and that it was required for caspase-1 
activation
91
. Therefore, we compared data for the tumor lesions of y-VAD-
treated vs IE-treated mice (Figure 19A) and we found that the inhibition of 
caspase-1 was associated to a reduction of the tumor lesion less pronounced 
than caspase-8 inhibition (P=0.0062 vs P<0.0001).  
Therefore to understand the role of both enzymes, we went on by treating 
NMU-exposed mice with both inhibitors y-VAD plus IE and then compared to 
the control group and to the group of mice that were solely treated with y-
VAD or IE. NMU-exposed-mice were treated with y-VAD (10µg/mouse)+IE 
(0.5µg/mouse) every two days intraperitoneally (i.p.) after NMU instillation. 
Animals were sacrificed at 7 and 28 days after the first exposure to NMU. At 
day 7 tumor size was significantly reduced after the administration of y-




19B). This result was comparable in size to the data obtained from IE-treated 
mice, confirming the hypothesis that caspase-8 acts upstream of caspase-1. 
Surprisingly, at a later time point (28 days after the initial NMU instillation), 
tumor lesion in y-VAD+IE-treated mice was comparable in size to those in 
CTR mice (Figure 19B).  
Therefore, further studies are needed to understand the interplay between these 
two enzymes during cancer-related inflammatory processes and effective role 
of the inflammasome activation-associated cell-death pathways.  
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Figure 19. The inhibition of both caspase-1 and caspase-8 did not alter 
lung tumor progression in mice. A) Comparison of the tumor lesion in CTR, 
y-VAD- and IE-treated mice. B) The inhibition of both caspase-1 and caspase-
8 was associated with a tumor lesion comparable in size to those in CTR mice. 
Data are expressed as medians±interquartile range and analyzed by using 





The controversial role of caspase-8 in cancer, stimulates the curiosity of 
numerous scientists. The enzyme has been determined to be highly versatile 
depending on the cellular context. It has a central role during apoptosis, but 
can also modulate inflammation propagation, two phenomenon that in an 
inverse manner, are strictly correlated to tumor outgrowth. Our data showed 
that pro-caspase-8 was expressed in human NSCLC samples. However, the 
active form of caspase-8 (22 kDa) was present in both ‘healthy, non-
cancerous’ and cancerous tissues. Similarly, lung tumor-bearing mice had high 
levels of the active form of caspase-8 after the exposure to the carcinogen. 
Though, the inhibition of caspase-8 by means of a specific inhibitor, z-IETD-
FMK, significantly reduced lung tumor burden accompanied by lower pro-
inflammatory cytokine release and innate immune suppressive cells (MDSCs), 
well-described to facilitate tumor progression
92
. In addition, both mouse and 
human samples showed that the limiting step for caspase-8 activity in tumor 
progression was related to the presence of the short segment of c-FLIP. 
Therefore, caspase-8 is an important orchestrator for cancer-associated 
inflammation and the presence of the short or long c-FLIP may represent the 
rheostat for caspase-8-induced tumor proliferation or tumor arrest/regression 
in the lung.  
Alteration of the expression of proteins involved in apoptosis is a common 
mechanism for tumor cells to evade the pharmacological treatment paving the 
way for drug resistance
93
. Unlike small cell lung cancer (SCLC), NSCLC, 
which represents the 80% of lung cancer diagnosis, highly expresses the 
precursor and the active form of caspase-8 (Figure 12A and 12B). However, 
the pro-apoptotic activity of caspase-8 depends on the levels of the short 
segment of c-FLIP
81,82
. Indeed, cancerous tissues of lung cancer in both mice 
and humans did not express c-FLIPs, instead, the long segment was 




preferentially heterodimerizes with it leading to an insufficient activity of 
caspase-8 to induce apoptosis, instead favoring cell survival
82
. Therefore, the 
limiting step for caspase-8-dependent pro-apoptotic activity was related to the 
presence of the short segment of c-FLIP. Healthy lung tissues had higher 
levels of c-FLIPs compared to the cancerous tissues, implying that the active 
form of caspase-8 in the tumor mass was not able to induce apoptosis but 
rather tumor cell proliferation. Indeed, the inhibition of caspase-8 by means of 
z-IETD-FMK reduced Ki-67 positive staining in the lung of tumor-bearing 
mice compared to the control group, implying that caspase-8 can facilitate 
tumor cell proliferation
66
. In support, the short isoform of c-FLIP was evident 
only in mice treated with z-IETD-FMK but not in the control group. Lamkanfi 
and colleagues, reported that the outcome of the pro-apoptotic activity of 
caspase-8 is most probably determined by the extend of its activation
94
. Our 
data show that the active form of caspase-8 in both human and mouse samples 
was not pro-apoptotic, but instead amplified tumor-associated inflammation. 
The levels of IL-6, TNFα, IL-18, IL-1α, IL-33, but not IL-1β, were 
significantly reduced in the lung of tumor-bearing mice treated with z-IETD-
FMK. The release of these cytokines was associated with STAT-3 activation, a 
transcription factor able to induce malignant cell proliferation by upregulating 
the expression of cell cycle regulators and of the anti-apoptotic genes
13
. 
Indeed, the levels of the anti-apoptotic Bcl-2 were not altered in tumor-bearing 
mice which were characterized by high levels of the active form of caspase-8. 
Moreover, we were not able to detect any activation of the effector pro-
apoptotic caspase-3, caspase-9 and cytochrome c (data not shown). However, 
it is to note that Bcl-2 levels were not modulated in the lung of tumor-bearing 
mice even after z-IETD-FMK treatment, implying that the inhibition of 
caspase-8 solely alters the inflammatory cytokine pattern without affecting the 




Moreover, because NF-kB activation and the amplification of the NF-kB-IL-
6/TNF-α-STAT-3 signaling cascade occur in most malignancies and facilitate 
pro-inflammatory and pro-survival gene expression
95
, and because it has been 
demonstrated that caspase-8 can orchestrate this pathway
75,82,94
, we observed 
that the inhibition of caspase-8 decreased the levels of IKKα, strictly related to 
NF-kB activation
66
. Therefore, we can speculate that caspase-8-dependent 
non-canonical inflammasome may represent the rheostat for tumor-associated 
inflammation. The activation of the inflammasome leads to IL-1β release
13
. In 
our conditions, we observed that IL-1β release was decreased only at early 
time points after the inhibition of caspase-8, implying that this cytokine plays 
redundant activities in our mouse model of lung cancer compared to the other 
pro-inflammatory cytokines, such as IL-18, IL-1α and IL-33.  
High serum concentrations of inflammasome-related IL-1-like cytokines are 
found in malignancies with low-rate survival from time of diagnosis
18
. These 
cytokines, directly or via the induction of TNF-α and IL-6
96
, are involved in 
cell proliferation and survival
97
, as well as cell adhesion and migration
21
, all 
features of tumor progression and invasiveness. Both pro-IL-1β, pro-IL-18 and 
pro-IL-33 are converted into their active form mainly by caspase-1-dependent 
canonical-inflammasome
15
. Although caspase-8 can substitute for caspase-1 
and can function as an efficient IL-1-converting enzyme for proteolytic 
maturation of IL-1β
15
, we have not detected significant differences in IL-1β 
release in the lung of Z-IETD-treated mice and control mice.  
Another cytokine associated with the inflammasome complex is IL-1α, an 
alarmin that unlike IL-1β, IL-18 and IL-33, does not require the cleavage by 







, IL-1α is released by dying cells, which stimulate 
oxidative stress pathways, responsible of local inflammation and in some cases 
of cell rescue from death to provide tissue regeneration and subsequent 
accumulation of mutations leading to tumor initiation/progression
27




of these findings, IL-1α-induced IL-6 activates STAT-3 and promotes liver as 
well as gastric tumorigenesis
21
. Besides its role in tumor-associated 
inflammation, IL-1α activity was also associated to the activity of mutated K-
Ras, one of the main oncogenes, that induces constitutive activation of NF-B 
and AP-1, which on one side can promote an autocrine loop for further IL-1α 
expression/secretion, and on the other increase tumor burden
100
. These 
processes were well-characterized in a mouse model of pancreatic carcinoma. 
To note, the activity of caspase-8 to induce inflammasome in a non-canonical 
manner has been described in cultured bone-marrow derived cells. Our data is 
the first, to our knowledge, to demonstrate that the active form of caspase-8 is 
involved in lung carcinogenesis in vivo in both humans and in a mouse model. 
In addition, the pharmacological inhibition of caspase-8 proved of anti-tumor 
activity and represents a novel data not only for the involvement of caspase-8 
in lung cancer but also for the involvement of the inflammasome in this 
context. Though, the presence of the short or long c-FLIP segment may 
represent the rheostat for caspase-8-induced tumor proliferation or tumor 
arrest/regression in the lung. 
However, the concomitant inhibition of both caspase-1 and caspase-8 in our 
mouse model of lung cancer does not reveal a reduction of tumor progression 
at 28 days, compared to the inhibition of inflammation at earlier time points (7 
days, Figure 19B).  Therefore, these data together the data show in Figure 8B 
in Chapter 1, implied that caspase-1 and caspase-8 are effector proteases 






Caspase-11-dependent non-canonical inflammasome was responsible of 
lung cancer establishment and progression. 
 
3.1 Introduction 
In the face of an ever-expanding bulk of literature on the role of caspase-11-
dependent non-canonical inflammasome during cell death pathways, very little 
is known about its role in cancer and particularly in cancer-associated 
inflammatory processes. 
It is widely described that caspase-11 contributes critically to host defense 
against bacterial pathogen by triggering pyroptotic cell death of infected 
myeloid cells
55,101
. Lamkanfi and colleagues suggested that LPS-induced 
mortality was predominantly due to caspase-11-dependent pyroptotic release 




Although, the release of “alarmins” such as IL-1α and HMGB1, have been 
detected in lung cancer tissues and were classified as negative prognostic 
biomarkers, no evidence correlated caspase-11 to cancer development. 
Furthermore, it seemed that caspase-11-dependent pyroptotic cell death 
occurred independently of the known inflammasome mediators NLRC4, 
NLRP3 and ASC
17
. In line with that, pro-inflammatory caspase-11 triggered 
caspase-1-independent macrophages death but, in response to a subset of 
inflammasome activators, it induced a caspase-1-dependent IL-1β and IL-18 
release, resulting in inflammatory response amplification. The interplay 
between caspase-11, caspase-1 and caspase-8 in cancer is still under-
investigated, but it is felt that a more thorough investigation of these pathways 






3.2 Materials and methods 
Mouse model. Female C57Bl/6, Caspase-11 ko (kindly provided by 
Genentech, USA), caspase-1/11 double ko (DKO), C3H/HeJ (C3H) mice 
(Charles River, Lecco Italy), were used (6-8 weeks old). Animals were 
subjected as described in Chapter 1, paragraph 1.2. Briefly, mice were exposed 
to NMU once a week for three consecutive weeks starting from a high dose of 
50μg/mouse (in 10 μl of saline) at week 1 followed by other two 
administrations of 10μg/mouse at week 2 and 3. Animals were sacrificed at 
different time points (7, 28 and 112 days) to study the involvement of caspase-
11 during lung cancer development and progression. Left lung lobes were 
embedded into OCT medium to perform H&E staining to evaluate the area of 
the tumor lesion, expressed as ratio of Tumor Lesion Area/Total Lung Area, 
calculated by means of ImageJ software (NIH, USA). Right lung lobes were 
digested with 1U/mL collagenase to perform flow cytometry analysis and to 
measure the release of pro-inflammatory cytokines (IL-1α, IL-1β, IL-18 and 
IL-33). 
Broncho-alveolar fluid (BAL) was collected by means of airway lavage by 
using a solution of PBS (0.5 mL) and EDTA (0.5 mM) to measure pro-
inflammatory (IL-1β and IL-18) cytokine levels.  
Isolation of alveolar macrophages. BAL-derived cells were cultured with 
RPMI supplemented with 10% FBS, L-Glutamine (2mM), penicillin 
(100U/ml) and streptomycin (100µg/ml) in an atmosphere of 5% CO2 at 37°C. 
Cells were plated for 1 hour to allow macrophages to attach before removing 









) and was around 85%. Cells were treated for 5 
hours with LPS (0.1µg/mL) and/or Glybenclamide (1µM). 
Bone-marrow (BM) transplant. Bone-marrow (BM) transplant experiments 
have been performed using wild type (wt, C57Bl/6 mice) and caspase-11 ko 




recipient mice were irradiated with one dose of 10 x rad to eliminate 
endogenous BM stem cells and most of the BM-derived cells, before the 
transplantation of 1x10
6 
donor BM cells, injected into the tail vein of recipient 
irradiated mice. Animals were divided in four groups: 1. donor wt cells into 
recipient wt mice (wt into wt); 2. donor caspase-11 ko cells into recipient 
caspase-11 ko mice (ko into ko); 3. donor wt cells into recipient caspase-11 ko 
mice (wt into ko); 4. donor caspase-11 ko cells into recipient wt mice (ko into 
wt).  
The degree of chimerism was assessed by FACS analysis of CD45
+
 blood 
leucocytes 7-8 weeks after BM transplant. NMU or vehicle were instilled 
starting at 8 weeks post BM transplant and chimera mice were sacrificed 28 
days after the first NMU exposure (Figure 23A). 
Cytokine measurements. IL-1α, IL-1β, IL-18 and IL-33 were measured in 
lung homogenates (expressed as pg/mg of proteins) and in BAL (expressed as 
pg/mL) by using commercially available ELISAs (eBioscience, CA, USA; 
R&D Systems, London, UK).  
Western blot analyses. Lung homogenates were used to examine the 
expression of caspase-11 active form (22kDa) vs the precursor form (55 kDa) 
(Santa Cruz Technologies, CA, USA). 
Statistical analysis. Results are expressed as median±interquartile range and 
analysed with Mann Whitney test for non parametric data. P values less than 










3.3 Results  
3.3.1 Caspase-11 was responsible of lung cancer progression in mice. 
In our previous data, we showed that the pharmacological inhibition of 
caspase-1 and caspase-8 reduced lung tumor lesions in NMU-exposed mice. 
This effect was more pronounced for mice where caspase-8 was inhibited. 
However, when both enzymes were pharmacologically inhibited we did not 
observe any reduction of tumor formation and progression, implying that the 
two enzymes are not pivotal for lung carcinogenesis. Moreover, double ko 
mice (Figure 9, Chapter 1) showed that the genetic absence of both caspase-1 
and caspase-11 induced a robustly reduced incidence of lung tumor in NMU-
exposed mice. Therefore, to define the role of caspase-11 during lung cancer 
establishment and progression, C57Bl/6 (CTR) and caspase-11 ko mice (solely 
ko for caspase-11 and not caspase-1) were treated with NMU and sacrificed at 
different time points. At 28 days and later time points (112 days) after NMU 
instillation, the genetic absence of caspase-11 significantly reduced tumor 
lesion area compared to CTR mice (Figure 20A). More importantly, we 
observed that at later time points (112 days), the tumor lesion was still low 
compared to CTR mice, implying that caspase-11 plays a pivotal role for lung 
carcinogenesis. Our previous data showed that the pharmacological inhibition 
of the caspase-8 and caspase-1, the latter is the final effector of the 
inflammasome activation, reduced lung cancer outgrowth associated to lower 
pro-inflammatory response and to a reduced lung recruitment of 
immunosuppressive cells. To investigate the role of caspase-11 and the 
possible co-operation with caspase-1, caspase-1/11 double ko (DKO) and 
caspase-11 ko NMU-exposed mice were compared in terms of tumor lesion. 
Surprisingly, at 28 days after the initial NMU instillation we did not observe 
any difference in terms of tumor lesion, between caspase-1/11 DKO e caspase-
11 ko (Figure 20B) implying that caspase-11, rather than caspase-1, is pivotal 




is upstream caspase-1 to induce the amplification of the occurring 
inflammatory process associated to lung cancer development, as demonstrated 
from experiments performed by pharmacologically inhibiting caspase-1 vs 
DKO (Figure 8B and 9, Chapter 1).  
Recent evidence suggested the involvement of TLR4 signaling in regulating 
caspase-11 expression and as the first signal for inflammasome activation in 
macrophages infected by pathogens
101
. To investigate whether this pathway/s 
was involved in our experimental model, C3H mice, which present a 
polymorphism on TLR4 gene in that the receptor lacks functional activity
102
, 
were used. NMU-exposed C3H mice did not report significant difference in 
terms of tumor lesion compared to CTR mice at 28 days, implying that TLR4 
signalling was dispensable for lung carcinogenesis (Figure 20C). These data 
are of particular interest in that caspase-11 was reported as the intracellular 
receptor for LPS after TLR4
103
. In our experimental data, the absence of 
activity of TLR4 in NMU-exposed C3H mice further confirmed the 
implication of caspase-11 in lung carcinogenesis.  
Taken together, these results reveal that caspase-11 is responsible for lung 
carcinogenesis in mice and that its activation (Figure 21A and 21B) leads to 
the canonical and non-canonical activation of the inflammasome during lung 




















































































































































Figure 20. Caspase-11 promoted cancer in the lung mice exposed to 
carcinogen. A) Caspase-11 ko mice showed a sharp reduction of tumor lesion 
compared to control mice (CTR) both at 28 and 112 days from the carcinogen 
instillation. After 28 days from the first exposure to NMU, the lung tumor 
lesion was similar in caspase-11 ko and caspase-1/11 double ko (DKO) (B) 
and in C3H mice compared to the CTR mice (C). Data are expressed as 
median±interquartile range and analyzed by means of Mann Whitney test for 















































Figure 21. Caspase-11 expression in naïve (non-treated) mice versus 
NMU-exposed mice (CTR), sacrificed at 28 days from the first NMU 
exposure. A) Representative western blots. B) Quantitative analysis 
performed by means of Image J (USA, NIH). Data are expressed as 





3.3.2 Caspase-11 modulated the inflammasome activation-dependent pro-
inflammatory pathway.  
Because the activation of the inflammasome leads to the release of IL-1-like 
cytokines
13
, in order to understand whether the activation of caspase-11 in our 
experimental model could lead to the release of these cytokines, we analyzed 
the levels of IL-1-like cytokines in both BAL and lung homogenates. NMU-
exposed caspase-11 ko, C3H and DKO mice had significantly reduced levels 
of IL-18 (Figure 22A); IL-1α (Figure 22B) and IL-33 (Figure 22C). Instead, 
IL-1β levels were solely reduced in DKO mice (Figure 22D), implying that 
this cytokine is strictly dependent on caspase-1 rather than caspase-11, 
although it works upstream caspase-1. Moreover, it is to note that C3H mice 
still had lower IL-18, IL-1α and IL-33 (Figure 22A, 22B and 22C), implying 
that although TLR4 is not involved in lung carcinogenesis, it can influence the 











































































Figure 22. The absence of caspase-11 was associated to a reduced release 
of pro-inflammatory cytokines from BAL and homogenates of NMU-
exposed mice. Caspase-11 ko mice released less IL-18 (A) in the BAL, but 
not IL-1β (D) compared to control. Similarly, the levels of IL-1α (B) and IL-
33 (C) were reduced in lung homogenates obtained from caspase-11 ko mice. 
Data are expressed as median±interquartile range. Significant differences were 





3.3.3 Caspase-11 in lung epithelial cells contributed to lung tumor 
progression by inducing IL-1α release from macrophages.    
The immune system is pivotal for malignant disease control in that failing 
immunity has been acknowledged for its contribution to cancer development 
and progression
21
. Tumor microenvironment is a complex scenario in which 




Canonical and non-canonical inflammasome activation has been described in 
both stromal and hematopoietic cells, although divergent function of the 
complex are reported depending on the experimental model and on the cell 
type. Because lung cancer originates from the malignant transformation 
occurred in the stromal, structural epithelial cells under carcinogen exposure, 
we wanted to evaluate what cell lineage, structural or hematopoietic, was 
majorly involved in caspase-11-induced lung cancer establishment and 
progression.  
Therefore, we performed bone-marrow (BM) transplant experiments by using 
wild type (wt, C57Bl/6 mice) and caspase-11 ko mice, as discussed in the 
materials and methods section of this Chapter. Animals were divided in four 
groups: 1. donor wt cells into recipient wt mice (wt into wt); 2. donor caspase-
11 ko cells into recipient caspase-11 ko mice (ko into ko); 3. donor wt cells 
into recipient caspase-11 ko mice (wt into ko); 4. donor caspase-11 ko cells 
into recipient wt mice (ko into wt). NMU or vehicle were instilled starting at 8 
weeks post BM transplant and chimera mice were sacrificed 28 days after the 
first NMU exposure (Figure 23A). Similarly to CTR and caspase-11 ko mice 
exposed to NMU, wt into wt and ko into ko group of mice showed similar 
levels of lung tumor lesion (Figure 23B). More importantly, the tumor lesion 
was significantly reduced in wt into ko group of mice that presented a wild 
type hematopoietic lineage and a caspase-11 ko structural (epithelial) lineage, 




to that of caspase-11 ko mice (Figure 23B). In contrast, the group of mice that 
received caspase-11 ko hematopoietic cells but presented a wild type recipient 
(structural cells) (ko into wt) still presented a significantly reduced lung tumor 
lesion compared to CTR; however, it was significantly higher than the group 
of wt into ko mice (Figure 23B). These data highlight the predominant role of 
caspase-11 in structural epithelial cells where it drives towards lung cancer 
establishment and progression, confirming our previous hypothesis.  
To better understand the role of epithelial vs hematopoietic cells in caspase-11 
activation-associated lung cancer, we moved on by analyzing the tumor 
immune microenvironment by focusing on macrophages because they are 
widely reported as populating tumor mass and as involved in tumorigenesis
77
. 
As shown in Figure 24A, the percentage of macrophages recruitment in the 
lung was reduced in C3H and DKO mice, but surprisingly it was similar 
between caspase-11 ko and CTR mice. Therefore, to better understand the role 
of caspase-11-dependent inflammasome in lung tumor-associated 
macrophages, we isolated and cultured alveolar macrophages from tumor-
bearing mice. Macrophages were stimulated for 5 hours with LPS (0.1µg/mL), 
a TLR4 ligand and well-known inflammasome activator
13
. The stimulation of 
CTR-derived alveolar macrophages with LPS induced a significant release of 
IL-1α compared to naïve, non-treated mice (Figure 24B). To verify the 
involvement of the inflammasome, cells were treated with a NLRP3 
inflammasome inhibitor glybenclamide (Gly, 1µM). IL-1α was significantly 
reduced in LPS+Gly-treated tumor lung macrophages (Figure 24C). Similarly, 
DKO mice showed that the genetic absence of both caspase-1 and caspase-11 
completely abrogated IL-1α release in LPS-treated tumor alveolar 
macrophages, implying a cross-talk between caspase-1 and caspase-11 (Figure 
24D). However, we observed that caspase-11 ko alveolar macrophages 
released significantly reduced levels of IL-1α when LPS was added (Figure 




governs over caspase-1 for the release of IL-1α from lung tumor associated 
macrophages.  
Taken together, these data demonstrate that tumor alveolar macrophages are 
able to release higher levels of IL-1α than macrophages derived by the lung of 
naïve mice, implying that the release of IL-1α by macrophages could favor 
lung carcinogenesis. Furthermore, tumor lung macrophages stimulated by LPS 















































































































Figure 23. Role of epithelial vs hematopoietic cells in caspase-11-mediated 
lung cancer establishment/progression. A) Bone-Marrow (BM) 
transplantation experimental protocol. The tumor lesion was reduced in wt into 
ko group, while it was increased in ko into wt group compared to caspase-11 
ko (B). Data are expressed as median±interquartile range. Statistical 
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Figure 24. Caspase-11 contributed to lung tumor progression by inducing 







 cells) recruited to the of NMU-exposed 
C57Bl/6, caspase-11 ko, C3H  and DKO mice. Lung tumor-associated 
macrophages released higher levels of IL-1α after LPS treatment compared to 
naïve lung-derived macrophages (B). The addition of LPS to glybenclamide-
treated lung tumor-associated macrophages significantly reduced IL-1α levels 
compared to cells treated with the sole LPS (C). The genetic absence of both 
caspase-1 and caspase-11 in DKO-derived macrophages obtained from NMU-
exposed mice completely abrogated the release of IL-1α after LPS stimulation 
(D). Macrophages obtained from NMU-exposed caspase-11 ko mice released 
significantly reduced levels of IL-1α when LPS was added (E). Data are 
expressed as median±interquartile range. Statistical differences were analyzed 





Here, we show that caspase-11 is involved in lung tumor formation associated 
with the amplification of inflammasome-dependent pro-inflammatory 
pathways. These data are of novel impact especially if we focus the attention 
on what reported in literature about the involvement of caspase-11 to induce 
Gasdermin-mediated cell death. In sharp contrast, we showed that the active 
form of caspase-11 was associated to lung tumor area. In support, Dr. 
Hornung’s laboratory showed that the activation of the human homologous of 
caspase-11 did not lead human monocytes to death, as demonstrated on 
murine bone marrow-derived macrophages. Here we want to pinpoint at the 
fact that the data reported in literature about the involvement of caspase-11 in 
cell death is mainly provided by using bone marrow-derived immortalized 
cells rather than primary and lung cancer-associated immune cells. 
In Chapter 1 and 2 we prove that both caspase-8 and caspase-1 are in their 
active form in human samples of lung cancer and in the lung of an 
experimental mouse model of lung cancer. However, their involvement to the 
inflammasome activation in lung cancer was related to an upstream 
orchestrator that we proved to be caspase-11. Caspase-11 ko mice showed a 
significant reduction of lung tumor formation.  
Subsequently, contrary to what is known about the protective role of the 
caspase-11 after damage signals, we demonstrate that the main orchestrator of 
lung cancer-associated inflammatory pathways is caspase-11-dependent non-
canonical inflammasome and that it is upstream caspase-1 to induce the 
amplification of the occurring inflammatory process associated to lung cancer 
development. Indeed, we observed that the pro-inflammatory IL-18, IL-1α, IL-
33, except for IL-1β, were significantly reduced in NMU-treated caspase-11 
ko mice- compared to the control.  
Another point to worthily focus on is the involvement of TLR4 in lung 
carcinogenesis. C3H mice, which lack a functional TLR4
102




similar lung tumor burden to control mice, implying that it is not involved in 
lung pro-carcinogenic pathway. However, our group published that TLR4 
activation by means of LPS can lead to lung tumor progression
104
. The 
discrepancy between these latter study could be due to the experimental mouse 
model. However, it is to note that Shi and colleagues, reported that the 
cytosolic receptor for LPS was caspase-11
103
. Thus, the apparent discrepancy 
could be avoided if we consider the actual experiments presented in this thesis. 
Indeed, it is plausible that what was observed in the published manuscript was 
still due to caspase-11 activation, that at that time was not widely described as 
the cytosolic receptor for LPS. Moreover, we cannot completely exclude the 
role of TLR4 in this pro-carcinogenic pathway since its functional activity in 
C3H mice showed reduced release of IL-1-like cytokines (Figure 22A, 22B, 
22C and 22D).  
In addition, of potential interest is the involvement of caspase-11 in the 
structural cells that lead to the formation of the tumor area versus the pro-
inflammatory role in the hematopoietic lineage. Experiments on conditional 
ablation of caspase-11 could be of further support of our data, but at the 
moment we do not display of these mice. Nonetheless, wt into ko mice group 
showed similar levels of lung tumor area as in case of caspase-11 ko compared 
to the control mice, implying its fundamental role in the structural lineage that 
can be influenced by the recruitment of the hematopoietic cells, most likely 
macrophages, that can collaborate with in a caspase-11-depdendent manner to 








Lung cancer is the leading cause of cancer death
1
, and it is widely accepted 
that chronic inflammation is an important factor risk for the development of 
this disease. Chronic inflammation, an aberrantly prolonged form of a 
protective host response to a loss of tissue homeostasis
105
, is linked to cancer 
development.  
The inflammasome has attracted considerable attention ever since its initial 
characterization due to its implication in the pathogenesis of several human 
inflammatory diseases
16
. It plays an important role in cellular repair and 
regeneration following acute damage, but if the signal persists, chronic or 
excessive inflammasome activity is likely to enhance chronic inflammation-
based diseases, as in case of malignancy.  
Despite increasingly widespread understanding of the inflammasome 
involvement in inflammation-driven cancer, the role of the complex during 
lung cancer establishment and progression remains a topic of intense 
investigation, since the information about it are few and conflicting.  
In the wake of this wave, our interest was projected to understand/investigate 
the role of the inflammasome in human lung cancer development taking 
advantage of a mouse model of carcinogen-induced lung cancer. We found 
that caspase-1, the primary protease associated to the canonical 
inflammasome, was in its active form in both human lung cancer samples and 
in a mouse model of lung carcinoma implying that rather than inducing cell 
death, it is involved in tumor proliferation. The pharmacological inhibition of 
the caspase-1 by means of Ac-Y-Vad significantly reduced lung cancer 
outgrowth associated to lower pro-inflammatory response and to a reduced 
recruitment of immunosuppressive cells (i.e. MDSCs and Treg) to the lung, 
implying a critical role for the caspase-1 during tumor immunoediting and 
tumor-associated inflammation. However, the inhibition of caspase-1 did not 




that caspase-1 may act in a non-inflammasome dependent manner or that it 
was just involved in IL-1α and IL-33 release, other two IL-1-like cytokines 
strictly dependent on inflammasome activation, or that another orchestrator 
might govern the effect of caspase-1 in our mouse model of lung cancer.  
Concurrently with our studies, Gurung and colleagues demonstrated that 
caspase-8-dependent non-canonical inflammasome was an upstream regulator 
of the caspase-1 in bone-marrow-derived macrophages (BMDMs) and that it 
was required for caspase-1 priming and activation
91
. Based on this concept, we 
moved on by analyzing the involvement of caspase-8 in our experimental 
model and the potential cross-talk between these two enzymes during lung 
cancer establishment and progression. We found that caspase-8 was in its 
active form in both humans and mice during lung carcinogenesis and that the 
pharmacological inhibition of the enzyme significantly reduced lung tumor 
burden accompanied by lower pro-inflammatory cytokines release in mice, 
without significantly affecting tumor immunoediting. However, it was 
demonstrated that the activity of caspase-8 as pro-apoptotic and pro-
inflammatory was strictly dependent on c-FLIP that in its long segment can 
inhibit caspase-8 favoring the pro-inflammatory involvement, whereas the 
short segment of c-FLIP can lead caspase-8 to pro-apoptotic pattern that ends 
in cells death
84
. In our human samples we found that the active form of 
caspase-8, present in both non-cancerous and cancerous tissues, was pro-
apoptotic in non-cancerous tissues in that it was associated to the expression of 
the short segment of c-FLIP, whereas its active form was involved in a pro-
tumor activity in lung cancer tissues. The experimental mouse data 
demonstrated that the pharmacological inhibition of the active form of 
caspase-8 significantly reduced lung tumor burden. However, the inhibition of 
both caspase-1 and caspase-8 gave surprising results in that it highlighted the 
role of another orchestrator in the complex scenario of lung carcinogenesis. 




exposed mice, effect that was maintained in a time-dependent manner (Figure 
20A).  
Based on the presented data, we could formulate two potential hypothesis. The 
first is that caspase-11 is indispensable for the inflammasome involvement in 
lung carcinogenesis, and it, upstream caspase-1 and caspase-8, orchestrates the 
inflammasome-dependent pro-inflammatory and pro-carcinogenic pathways 
(Figure 25). However, due to the relevance of caspase-11 in lung 
carcinogenesis, as also demonstrated by specific knockout mice, it is plausible 
and tempting to speculate that besides the pro-inflammatory/pro-carcinogenic 
role of caspase-11 upstream caspase-1 and caspase-8, another signaling 
mechanism strictly dependent on caspase-11, probably in an inflammasome-
independent manner, can occur. This hypothesis is supported by the fact that 
the pharmacological inhibition of caspase-1 and caspase-8 (Figure 19A and 
19B), leaves unaltered the activity of caspase-11, which could still induce a 
pro-carcinogenic stimulus for lung cancer establishment and progression. To 
further understand, we performed additional experiments  (not presented in 
this thesis) that proved that the active form of caspase-11 and its human 
homologous can bind p53 and most probably sequester it from its 
oncosuppressive activity. The latter data need further elucidation but opens 
new perspectives to understand the biology of caspase-11 in an 
inflammasome-dependent and –independent manner.  
In conclusion, we identify a novel mechanism by which lung-associated 
inflammation due to the exposure to a genotoxic stimulus, can lead to 
malignancy. 
In this scenario, caspase-11 plays a pivotal role in that it favors both a pro-
inflammatory and pro-carcinogenic pattern. This effect was principally 
associated to the expression of caspase-11 in the structural epithelial cells, but, 
however, to the expression/activity in the hematopoietic cells lineage. In 




the activation of caspase-11-dependent inflammasome due to the release of the 
pro-tumorigenic IL-1α. Tumor-associated alveolar macrophages were able to 
release higher levels of IL-1α than macrophages derived by the lung of naïve 
(non-treated) mice, implying that the release of IL-1α by macrophages could 
favor lung carcinogenesis. It is well reported the correlation between the levels 
of IL-1α in human lung cancer tissues and the bad prognosis of patients
76
. 
Moreover, this effect is also associated to the capability of IL-1α to interfere in 
K-Ras-dependent signaling.  
Despite the satisfactory results we obtained to increase the knowledge on the 
inflammasome biology in lung tumor microenvironment pointing at this 
complex as a promising therapeutic strategy against lung cancer, there are still 
many unanswered questions. Therefore, further studies are needed to 
understand what is/are the upstream inflammasome regulators, what is the role 
of pyroptosis in this context and how to demonstrate that this cell death 
pathway associated to inflammasome activation is pro- or anti-tumor, 
considering the lack of specific methodologies/tools for in vivo studies. 
Although our data demonstrate the effective involvement of the caspase-1-, 
caspase-8- and caspase-11-dependent inflammasome during lung cancer 
establishment and progression in both mice and humans, the exact interplay 
between these enzyme in cancer is still doubtful, but it is felt that a more 
thorough investigation of these pathways in carcinogenesis may help reconcile 










Figure 25. Caspase-11 orchestrates caspase-8- and caspase-1-dependent 
inflammasome during lung carcinogenesis. In particular, it is involved in both 
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